FPFT-2216, a novel anti-lymphoma compound, induces simultaneous degradation of IKZF1/3 and CK1α to activate p53 and inhibit NF-κB signaling
Article in Cancer Research Communications (February 2024)
The most recent citing publications are shown below. View all 4 publications that cite this research output on Dimensions.
Article in Cancer Research Communications (February 2024)
Article in Science Signaling (October 2023)
Article in Cancers (August 2022)